Dayvigo generic is expected to become available after 21 October, 2035. This date corresponds to the expiration of the last patent held for the drug. Drug patent challenges can start to be filed against Dayvigo from 7th April 2024.
Dayvigo is used in the treatment of adult patients suffering from insomnia, which is characterized by difficulties with sleep onset and/or sleep maintenance. The drug leverages lemborexant to effectively address these issues.
Dayvigo has two patents in effect. The final patent, titled 'Compositions and methods for treating insomnia', is set to expire on 21 October, 2035. This date indicates when the Dayvigo generic could potentially be made available. Below are the details of the patent: